Scott F W, Forsdyke D R
Biochem J. 1980 Sep 15;190(3):721-30. doi: 10.1042/bj1900721.
It is presumed that the dGTP and dATP needed for replicative DNA synthesis can be formed by way of either ;salvage' pathways or biosynthesis de novo. This was examined by adding hydroxyurea to cultures of rat thymus cells to inhibit ribonucleoside diphosphate reductase, a key enzyme of the ;de novo' pathway. Most of the inhibition of the incorporation of [Me-(3)H]thymidine and deoxy[5-(3)H]cytidine by low concentrations of hydroxyurea (100-500mum) was prevented by substrates of the salvage pathway (400mum-deoxyguanosine and, to a lesser extent, 200mum-deoxyadenosine). However, isotope-dilution studies indicated that the purine deoxyribonucleosides prevented inhibition by decreasing pyrimidine deoxyribonucleotide competitor pools. Evidence was obtained that a hydroxyurea-induced increase in the thymidine-competitor pool (probably dTTP) was prevented to an equal extent by deoxyguanosine and by the inhibitor of thymidylate synthase, deoxy-5-fluorouridine. These compounds had almost identical effects on hydroxyurea dose-response curves and on thymidine isotope-dilution plots. The evidence suggests that exogenous purine deoxyribonucleosides cannot prevent the inhibition by hydroxyurea of thymus-cell DNA synthesis. This could mean that, with respect to the metabolism of purine deoxyribonucleotides, ribonucleoside diphosphate reductase is tightly coupled to DNA polymerase in a multienzyme complex. The complex would not permit entry of exogenous metabolic intermediates into the ;de novo' pathway, but would still be subject to the regulatory effects of these intermediates. Thus dGTP and dATP formed from exogenous purine deoxyribonucleosides by salvage pathways might deplete pyrimidine deoxyribonucleotide competitor pools by inhibiting relatively hydroxyurea-insensitive activities of ribonucleoside diphosphate reductase.
据推测,复制性DNA合成所需的dGTP和dATP可以通过“补救”途径或从头生物合成形成。通过向大鼠胸腺细胞培养物中添加羟基脲以抑制核糖核苷二磷酸还原酶(从头途径的关键酶)来对此进行研究。低浓度羟基脲(100 - 500μM)对[甲基 - (3)H]胸苷和脱氧[5 - (3)H]胞苷掺入的大部分抑制作用可被补救途径的底物(400μM - 脱氧鸟苷,以及程度较小的200μM - 脱氧腺苷)阻止。然而,同位素稀释研究表明,嘌呤脱氧核糖核苷通过减少嘧啶脱氧核苷酸竞争池来阻止抑制作用。有证据表明,脱氧鸟苷和胸苷酸合酶抑制剂脱氧 - 5 - 氟尿苷在同等程度上阻止了羟基脲诱导的胸苷竞争池(可能是dTTP)增加。这些化合物对羟基脲剂量反应曲线和胸苷同位素稀释图几乎具有相同的影响。证据表明,外源性嘌呤脱氧核糖核苷不能阻止羟基脲对胸腺细胞DNA合成的抑制作用。这可能意味着,就嘌呤脱氧核苷酸的代谢而言,核糖核苷二磷酸还原酶在多酶复合物中与DNA聚合酶紧密偶联。该复合物不允许外源性代谢中间体进入从头途径,但仍会受到这些中间体的调节作用。因此,通过补救途径由外源性嘌呤脱氧核糖核苷形成的dGTP和dATP可能通过抑制核糖核苷二磷酸还原酶相对对羟基脲不敏感的活性来消耗嘧啶脱氧核苷酸竞争池。